What it's for (Indications)
- Albumin Human is indicated for the restoration and maintenance of circulating blood volume in situations where volume deficiency has been demonstrated, and the use of a colloid is appropriate.
- Primary indications include conditions associated with hypovolemic shock, such as acute blood loss (hemorrhage), trauma, or extensive burns, to aid in immediate volume expansion and stabilize hemodynamics.
- It is also utilized in various forms of hypoalbuminemia where replacement is deemed clinically necessary to address depleted plasma protein levels and maintain colloidal osmotic pressure.
- Specific hypoalbuminemic indications may include severe burns with substantial protein loss, adult respiratory distress syndrome (ARDS), the management of ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis, and in certain cases of nephrotic syndrome for transient volume expansion and diuresis.
- Additionally, it may be used as a replacement fluid during plasma exchange procedures, for the prevention of circulatory dysfunction following large-volume paracentesis in cirrhotic patients, and in the treatment of hyperbilirubinemia in neonates to bind unconjugated bilirubin prior to exchange transfusion.
- The decision to administer albumin should be based on clinical assessment, serum albumin levels, and the overall pathophysiological state of the patient, considering its role in maintaining oncotic pressure and transporting various substances.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of Albumin Human is highly individualized and must be determined by a healthcare professional based on the patient's clinical condition, age, body weight, the specific indication for use, and the desired therapeutic effect. It is available in 5% (50 mg/mL) and 25% (250 mg/mL) solutions for intravenous infusion. For hypovolemic shock, initial doses for adults may range from 25 grams (e.g., 500 mL of 5% solution or 100 mL of 25% solution), administered rapidly if necessary, with subsequent doses guided by hemodynamic response and fluid balance. For children, a typical starting dose for hypovolemia is 0.5 to 1 gram per kilogram of body weight. In hypoalbuminemia, the infusion rate is generally slower, with adult doses often being 25 grams daily or every other day, titrated according to serum albumin levels and clinical signs of improvement. For large-volume paracentesis in cirrhotic patients, a common recommendation is 6-8 grams of albumin per liter of ascites removed. In neonates with hyperbilirubinemia, a dose of 1 gram per kilogram may be administered prior to exchange transfusion. The rate of infusion should be carefully adjusted to prevent circulatory overload, particularly in patients with cardiac or renal impairment. Close monitoring of vital signs, fluid balance, and central venous pressure is essential throughout the administration to avoid potential complications. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated, Albumin Human can induce a range of side effects, most of which are mild and transient.
- Common adverse reactions include flushing, urticaria (hives), skin rash, fever, chills, nausea, vomiting, and headache.
- These symptoms often subside with a reduction in the infusion rate or temporary discontinuation of the product.
- More serious, albeit less common, side effects primarily involve cardiovascular and allergic reactions.
- There is a significant risk of **circulatory overload** or **hypervolemia**, especially with rapid infusion or in patients with compromised cardiac or renal function, which can manifest as dyspnea, pulmonary edema, elevated blood pressure, or increased central venous pressure.
- Therefore, careful monitoring of cardiovascular and respiratory status is crucial.
- **Allergic or anaphylactic reactions**, though rare, can be severe and life-threatening, presenting as bronchospasm, hypotension, angioedema, or generalized urticaria.
- Should such reactions occur, the infusion must be stopped immediately, and appropriate emergency treatment initiated.
- Other potential, less frequent side effects include electrolyte imbalances, particularly hypernatremia due to the sodium content in some formulations, and in very large volumes, dilution of coagulation factors leading to a transient coagulopathy.
- Very rarely, transfusion-related acute lung injury (TRALI) has been reported with plasma protein products.
- All healthcare providers should be vigilant for these potential adverse events during and after administration.
Serious Warnings
- Black Box Warning: While Albumin Human does not carry an FDA Black Box Warning, its use is associated with several serious risks that necessitate careful consideration and vigilant patient monitoring. The primary serious warnings revolve around the potential for **circulatory overload** and **severe hypersensitivity reactions**. Rapid administration or administration of large volumes, especially in patients with pre-existing cardiac insufficiency, severe anemia, hypertension, or pulmonary edema, can precipitate or worsen acute pulmonary edema, congestive heart failure, or other manifestations of hypervolemia. Symptoms such as dyspnea, orthopnea, elevated central venous pressure, or hypertension warrant immediate cessation or significant reduction of the infusion rate. Furthermore, although rare, **anaphylactic or anaphylactoid reactions** can occur, characterized by symptoms ranging from urticaria and rash to severe bronchospasm, hypotension, and angioedema. Healthcare providers must be prepared to manage such allergic emergencies immediately with appropriate interventions. Careful assessment of the patient's fluid status, cardiac function, and vital signs before and during albumin infusion is paramount to mitigate these potentially life-threatening complications. Physicians should weigh the potential benefits against these significant risks for each individual patient.
- The administration of Albumin Human necessitates careful consideration of several critical warnings to ensure patient safety.
- A paramount concern is the potential for **circulatory overload** due to its plasma volume-expanding properties.
- Patients with pre-existing cardiac insufficiency, severe anemia, hypertension, or pulmonary edema are particularly vulnerable to developing or exacerbating congestive heart failure or acute pulmonary edema.
- Close monitoring of hemodynamic parameters, fluid balance, and respiratory status is imperative, and the infusion rate should be meticulously controlled and adjusted.
- Should signs of hypervolemia (e.
- g.
- , dyspnea, increased blood pressure, elevated central venous pressure) develop, the infusion must be stopped or significantly slowed.
- Another serious warning pertains to **hypersensitivity reactions**.
- Although rare, severe allergic reactions, including anaphylaxis, can occur.
- Patients should be observed for signs such as urticaria, rash, flushing, hypotension, bronchospasm, or angioedema.
- Emergency measures must be readily available to manage these reactions.
- Due to the sodium content in certain albumin formulations, caution is advised in patients requiring strict sodium restriction or those with impaired renal function, as it may contribute to **electrolyte imbalances** or fluid retention.
- While derived from human plasma, modern manufacturing processes, including pasteurization, are designed to inactivate viruses; however, the theoretical risk of transmitting infectious agents, including prions or unknown viruses, cannot be entirely excluded, although no confirmed cases of viral transmission have been associated with currently available albumin products.
- In situations requiring massive transfusions, the dilution of plasma proteins and coagulation factors might rarely lead to a transient **coagulopathy**.
- Specific patient populations, such as those with severe anemia, heart failure, or renal insufficiency, require increased caution and meticulous monitoring during albumin administration.
How it Works (Mechanism of Action)
Albumin, a large globular protein, is the most abundant protein in human plasma, accounting for approximately 60% of total plasma protein. Its therapeutic efficacy is primarily attributed to its significant contribution to maintaining **colloidal osmotic pressure (COP)** within the intravascular compartment. By exerting oncotic pressure, albumin effectively draws fluid from the interstitial space into the circulation, thereby increasing and maintaining plasma volume. This volume-expanding effect is crucial in conditions of hypovolemia, shock, and severe burns, where it helps restore circulating blood volume and stabilize hemodynamic parameters. Beyond its role in oncotic pressure, albumin serves as a vital non-specific **transport protein** for a diverse array of endogenous and exogenous substances. These include hormones (e.g., thyroid hormones, cortisol), fatty acids, bilirubin, metal ions, and various therapeutic drugs (e.g., warfarin, phenytoin, salicylates). This binding capacity influences the distribution, metabolism, and elimination of these substances. Furthermore, albumin exhibits **antioxidant properties**, acting as a scavenger of free radicals and helping to protect tissues from oxidative damage. It also contributes significantly to the **buffering capacity** of blood, aiding in the maintenance of physiological pH. In critical illness, albumin may also play a role in modulating inflammation and maintaining microvascular integrity, although these mechanisms are less precisely defined. Therapeutic administration aims to supplement or restore these multifarious physiological functions when endogenous albumin levels are insufficient or when rapid intravascular volume expansion is required.